We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Serum Free Light Change in Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00910078
Recruitment Status : Completed
First Posted : May 29, 2009
Last Update Posted : May 29, 2009
Sponsor:
Information provided by:

Study Description
Brief Summary:
The purpose of this study is to evaluate the predictive role of free Kappa/Lambda ration in Multiple Myeloma post-transplant.

Condition or disease
Multiple Myeloma

Study Design

Study Type : Observational
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Serum Free Light Chain Ratio, Total Kappa/Lambda Ratio, and Immunofixation as Prognostic Factors in Multiple Myeloma.

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma
U.S. FDA Resources

Groups and Cohorts


Outcome Measures

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
A cohort of patients undergoing autolog transplantatio
Criteria

Inclusion Criteria:

  • Patients affected with Multiple Myeloma who underwent autologous or auto/allogenic stem cell transplantation.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00910078


Locations
Italy
Azienda Ospedaliera S. Giovanni Battista
Torino, Italy, 10126
Sponsors and Collaborators
Azienda Ospedaliera San Giovanni Battista
More Information

ClinicalTrials.gov Identifier: NCT00910078     History of Changes
Other Study ID Numbers: sFLC r, KLR and IFIX
First Posted: May 29, 2009    Key Record Dates
Last Update Posted: May 29, 2009
Last Verified: May 2009

Keywords provided by Azienda Ospedaliera San Giovanni Battista:
Total kappa and lambda ratio
Stem cell transplantation
Serum immunofixation

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases